These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 1711366)
21. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Benson MC Ann Oncol; 1999 Nov; 10(11):1269-70. PubMed ID: 10631452 [No Abstract] [Full Text] [Related]
22. [Systemic chemotherapy in advanced bladder cancer. New aspects]. Jakse G Wien Klin Wochenschr; 1987 Jan; 99(2):54-7. PubMed ID: 3564487 [TBL] [Abstract][Full Text] [Related]
23. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract. Koch MO; Coussens D Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122 [No Abstract] [Full Text] [Related]
25. [Systemic chemotherapy for transitional cell carcinoma of the urothelium]. Lehmann J; Retz M; Hack M; Siemer S; Stöckle M Onkologie; 2003 Oct; 26 Suppl 4():18-25. PubMed ID: 14605452 [TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder. McLaren DB Clin Oncol (R Coll Radiol); 2005 Oct; 17(7):503-7. PubMed ID: 16238137 [TBL] [Abstract][Full Text] [Related]
27. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma. Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565 [TBL] [Abstract][Full Text] [Related]
28. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen. Sternberg CN; Yagoda A; Scher HI Prog Clin Biol Res; 1988; 277():45-51. PubMed ID: 3054909 [No Abstract] [Full Text] [Related]
29. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer. Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736 [TBL] [Abstract][Full Text] [Related]
30. Chemotherapy of advanced transitional-cell carcinoma of the bladder. Miller RS; Torti FM Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829 [TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder. Miller RJ; Bahnson RR; Banner B; Ernstoff MS; O'Donnell WF Cancer; 1990 Jan; 65(2):207-10. PubMed ID: 2295043 [TBL] [Abstract][Full Text] [Related]
32. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Mead GM; Russell M; Clark P; Harland SJ; Harper PG; Cowan R; Roberts JT; Uscinska BM; Griffiths GO; Parmar MK Br J Cancer; 1998 Oct; 78(8):1067-75. PubMed ID: 9792152 [TBL] [Abstract][Full Text] [Related]
33. Extended experience of neo-adjuvant M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder. Keating JP; Zincke H; Hahn RG; Morgan WR Prog Clin Biol Res; 1990; 353():119-27. PubMed ID: 2217409 [No Abstract] [Full Text] [Related]
34. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers]. Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308 [TBL] [Abstract][Full Text] [Related]
36. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. Boutan-Laroze A; Mahjoubi M; Droz JP; Charrot P; Fargeot P; Kerbrat P; Caty A; Voisin PM; Spielmann M; Rey A Eur J Cancer; 1991; 27(12):1690-4. PubMed ID: 1782084 [TBL] [Abstract][Full Text] [Related]
37. Oral piritrexim in advanced bladder cancer: an effective drug after progression on MVAC chemotherapy? Feun LG; Savaraj N; Benedetto P; Waldman S; Collier M; Clendennin NJ Am J Clin Oncol; 1994 Oct; 17(5):448-51. PubMed ID: 8092120 [TBL] [Abstract][Full Text] [Related]
38. Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study. Dreicer R; Messing EM; Loehrer PJ; Trump DL J Urol; 1990 Nov; 144(5):1123-6; discussion 1126-7. PubMed ID: 2231884 [TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy in invasive bladder cancer: the evolving role of surgery. Herr HW; Whitmore WF; Morse MJ; Sogani PC; Russo P; Fair WR J Urol; 1990 Nov; 144(5):1083-8. PubMed ID: 2231876 [TBL] [Abstract][Full Text] [Related]
40. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]